Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of BKM120 With Thoracic Radiotherapy in NSCLC
NCT02128724Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Apr 2013
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buparlisib in non-small cell lung cancer (NSCLC), sponsored by University of Oxford. Primary endpoints: Number of Dose Limiting Toxicities Observed in Evaluable Patients at 8 weeks and Patients With Buparlisib Related Adverse Events at 8 weeks. Started Apr 2013; status: completed.
02
Drugs
buparlisib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02128724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02128724.